Search
Canagliflozin
go.drugbank.com/drugs/DB08907ApprovedInvestigationalIt was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type … Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes [L5897].
Mixtures: VOKANAMET TM TABLETAS RECUBIERTAS 50 / 1000MGTetracosactide
go.drugbank.com/drugs/DB01284ApprovedInvestigationalTetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. … Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone.
Trovafloxacin
go.drugbank.com/drugs/DB00685ApprovedWithdrawnIt was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. … Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseCefmenoxime
go.drugbank.com/drugs/DB00267ApprovedIt is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UsePhenytoin
go.drugbank.com/drugs/DB00252ApprovedInvestigationalVet approved[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for several other indications … [A188826,A188832] Clinicians are advised to initiate therapeutic drug monitoring in patients who require phenytoin since even small deviations from the recommended therapeutic range can lead to suboptimal
Products: FENIFFLER-TVonoprazan
go.drugbank.com/drugs/DB11739ApprovedInvestigationalPCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. … [A253707] In February 2015, vonoprazan was first marketed in Japan for the treatment of acid-related disorders and as an adjunct to _Helicobacter pylori_ (_H. pylori_) eradication.
Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)Viltolarsen
go.drugbank.com/drugs/DB15005ApprovedInvestigationalfor exon 53 skipping. … [A218186] Hence, viltolarsen is similar to another PMO, [eteplirsen], which gained FDA approval on September 19, 2016; however, [eteplirsen] is specific for exon 51 skipping while viltolarsen is specific
Celiprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnCeliprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. … Celiprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome.
Crovalimab
go.drugbank.com/drugs/DB16128ApprovedInvestigational[L50933] Unlike other complement inhibitors previously approved for PNH, crovalimab uses a mechanism called anti-C5 sequential monoclonal antibody recycling technology that allows the drug to bind to … [L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Promazine
go.drugbank.com/drugs/DB00420ApprovedVet approvedWithdrawnA phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. … It is currently not approved for use in the United States.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome